Sign In
Buy XTLB
$2.70
+0.160 (+6.30%)
At Close: Jun 22, 2026
XTL Announces Receipt of Staff Delist Determination from Nasdaq
04:10pm, Friday, 22'nd May 2026
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Let
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum
XTL Biopharmaceuticals Announces ADS Ratio Change
04:10pm, Friday, 20'th Mar 2026
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of it
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
04:30pm, Friday, 27'th Feb 2026
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Le
XTL Update on Recent Developments
04:05pm, Thursday, 29'th Jan 2026
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acq
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
04:10pm, Friday, 23'rd Jan 2026
RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification lett
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
09:28am, Tuesday, 13'th Jan 2026
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
04:00pm, Wednesday, 24'th Dec 2025
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification lett
XTL Names Mr. Noam Band as its New Chief Executive Officer
09:15am, Monday, 07'th Apr 2025
Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
09:15am, Wednesday, 14'th Aug 2024
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5
XTL Entered Definitive Agreement to Acquire The Social Proxy
09:15am, Wednesday, 05'th Jun 2024
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Pla
XTL To Aquire The Social Proxy
10:15am, Wednesday, 20'th Mar 2024
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Place
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
04:00pm, Friday, 20'th Oct 2023
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
04:00pm, Friday, 20'th Oct 2023
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co
JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.
